Chimerix: Thinking on the Stock in the Aftermath of Results from the AdVise Trial (CMRX, $4.95)Tuesday, May 10, 2016 · 10:44 am |
|
Chimerix: An Intriguing Near Term and Long Term Outlook for the Stock (CMRX, Buy, $5.67)Thursday, April 14, 2016 · 4:43 pm |
|
Chimerix: Upgrading the Stock to a Buy (CMRX. Buy, $6.10)Tuesday, January 5, 2016 · 10:10 am |
|
Chimerix: An Update (CMRX, $52.83, Neutral)Monday, August 10, 2015 · 8:26 am |
|
Chimerix: A Review of Recent Analyst Day Presentations with a Focus on Adenovirus and Ebola (CMRX, $31.31, Neutral)Monday, October 20, 2014 · 12:45 pm |
|
Chimerix: Moving to a Buy (CMRX, $14.22, Paid subscribers)Wednesday, May 21, 2014 · 9:33 am |
|
Chimerix is A Company Focused on Infectious Viral Diseases that Has Investment Characteristics Similar to Trius (CMRX, Neutral, $25.48) (Subscribers Only)Thursday, March 13, 2014 · 12:06 pm |
|
The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)Friday, February 14, 2014 · 4:28 pm |
|
|
There are 8 reports on file. |
